NBIX Neurocrine Biosciences Inc

Price (delayed)

$104.54

Market cap

$9.89B

P/E Ratio

26.74

Dividend/share

N/A

EPS

$3.91

Enterprise value

$9.96B

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights
The company's equity has surged by 54% YoY and by 6% QoQ
The price to earnings (P/E) is 35% lower than the last 4 quarters average of 41.1
Neurocrine Biosciences's quick ratio has soared by 155% YoY but it has decreased by 9% from the previous quarter
The company's net income has surged by 78% YoY but it fell by 9% QoQ

Key stats

What are the main financial stats of NBIX
Market
Shares outstanding
94.65M
Market cap
$9.89B
Enterprise value
$9.96B
Valuations
Price to earnings (P/E)
26.74
Price to book (P/B)
7.73
Price to sales (P/S)
9.58
EV/EBIT
101.44
EV/EBITDA
92.49
EV/Sales
9.65
Earnings
Revenue
$1.03B
EBIT
$98.2M
EBITDA
$107.7M
Free cash flow
$248.2M
Per share
EPS
$3.91
Free cash flow per share
$2.62
Book value per share
$13.53
Revenue per share
$10.91
TBVPS
$20.68
Balance sheet
Total assets
$1.96B
Total liabilities
$677.2M
Debt
$435.3M
Equity
$1.28B
Working capital
$897.2M
Liquidity
Debt to equity
0.34
Current ratio
5.21
Quick ratio
4.9
Net debt/EBITDA
0.62
Margins
EBITDA margin
10.4%
Gross margin
98.9%
Net margin
35.3%
Operating margin
11.8%
Efficiency
Return on assets
20.7%
Return on equity
33%
Return on invested capital
6.2%
Return on capital employed
5.6%
Return on sales
9.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
1.86%
1 week
0.44%
1 month
8.51%
1 year
4.72%
YTD
9.07%
QTD
9%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$1.03B
Gross profit
$1.02B
Operating income
$121.8M
Net income
$364.7M
Gross margin
98.9%
Net margin
35.3%
The company's net income has surged by 78% YoY but it fell by 9% QoQ
The net margin has soared by 73% YoY but it is down by 8% QoQ
The operating margin has plunged by 57% YoY and by 9% from the previous quarter
The operating income has dropped by 56% year-on-year and by 10% since the previous quarter

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
P/E
26.74
P/B
7.73
P/S
9.58
EV/EBIT
101.44
EV/EBITDA
92.49
EV/Sales
9.65
NBIX's EPS has surged by 76% year-on-year but it is down by 9% since the previous quarter
The price to earnings (P/E) is 35% lower than the last 4 quarters average of 41.1
The company's equity has surged by 54% YoY and by 6% QoQ
NBIX's price to book (P/B) is 47% lower than its 5-year quarterly average of 14.6 and 9% lower than its last 4 quarters average of 8.5
The stock's price to sales (P/S) is 86% less than its 5-year quarterly average of 66.4 but 10% more than its last 4 quarters average of 8.7
Neurocrine Biosciences's revenue has increased by 2.6% YoY

Efficiency

How efficient is Neurocrine Biosciences business performance
The company's return on invested capital has shrunk by 69% YoY and by 33% QoQ
NBIX's return on sales has dropped by 62% year-on-year and by 21% since the previous quarter
Neurocrine Biosciences's return on assets has increased by 35% YoY but it has decreased by 15% QoQ
The ROE has contracted by 19% from the previous quarter but it has grown by 10% YoY

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
NBIX's total assets is 189% more than its total liabilities
The company's current ratio has surged by 161% YoY but it fell by 9% QoQ
Neurocrine Biosciences's quick ratio has soared by 155% YoY but it has decreased by 9% from the previous quarter
The debt is 66% lower than the equity
The company's equity has surged by 54% YoY and by 6% QoQ
NBIX's debt to equity is down by 44% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.